Overview

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority

Status:
Not yet recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

This program is a comprehensive evaluation of rheumatic valvular heart disease (RVHD), Atrial fibrillation (AF)/flutter and stroke. A prospective, randomized, open-label superiority trial comparing rivaroxaban to aspirin in high risk patients either with AF and unsuitable for VKA or without AF and with high risk factors.

Phase:

Phase 3

Details

Lead Sponsor:

Population Health Research Institute

Collaborator:

University of Cape Town

Treatments:

Aspirin
Rivaroxaban
Vitamin K